Compounds > rosiglitazone
Page last updated: 2024-08-25

rosiglitazone and Peritoneal Diseases

rosiglitazone has been researched along with Peritoneal Diseases in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Biçak, S; Bozkurt, D; Duman, S; Ok, E; Sen, S; Sezak, M; Taskin, H1
Aroeira, LS; González-Mateo, GT; López-Cabrera, M; Ortiz, A; Ruiz-Ortega, M; Selgas, R1

Other Studies

2 other study(ies) available for rosiglitazone and Peritoneal Diseases

ArticleYear
Rosiglitazone, a peroxisome proliferator-activated receptor agonist, improves peritoneal alterations resulting from an encapsulated peritoneal sclerosis model.
    Advances in peritoneal dialysis. Conference on Peritoneal Dialysis, 2008, Volume: 24

    Topics: Animals; Female; Peritoneal Dialysis; Peritoneal Diseases; Peritoneum; Peroxisome Proliferator-Activated Receptors; Rats; Rats, Wistar; Rosiglitazone; Sclerosis; Thiazolidinediones

2008
Pharmacological modulation of peritoneal injury induced by dialysis fluids: is it an option?
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2012, Volume: 27, Issue:2

    Topics: Animals; Celecoxib; Dialysis Solutions; Disease Models, Animal; Enalapril; Female; Humans; Male; Mice; Peritoneal Dialysis; Peritoneal Diseases; Peritoneum; Pharmaceutical Preparations; Prospective Studies; Pyrazoles; Rats; Rosiglitazone; Sensitivity and Specificity; Sulfonamides; Thiazolidinediones

2012